Additionally, the phase 2 MOMENTUM clinical trial of pemvidutide (a dual GLP-1/GCG agonist) showed that only 21.9% of WL was attributable to reductions in lean mass at 48 weeks (overall WL 10.315.6% across doses) [64]
However, many patients require treatment more frequently than current guidelines suggest
Diabetes Care 47 , 17181730 (2024)

Embody GLP-1 Pros and Cons Pros Oral tirzepatide gum is one of the few non-injectable tirzepatide options available through telehealth Fast clinical turnaround, with prescriptions typically reviewed in under 24 hours Medication ships within one to two days of approval Flat-rate pricing locked in at signup, with no dose-related increases 24/7 nursing and specialist support included with every plan Full refund if your prescription isnt approved HSA and FSA eligible, and insurance isnt required Four format combinations available across semaglutide and tirzepatide, covering both injectable and oral options Plans can be paused or adjusted rather than only cancelled outright First month includes a personalized metabolic report and a one-on-one provider session Cons Requires sign-off from a licensed healthcare provider before any medication ships Results vary from one person to the next Primarily accessible through the official website Not available in Mississippi or Louisiana, so coverage isnt nationwide How We Researched and Rated Embody GLP-1 Embody GLP-1 was evaluated on clinical credibility, medication quality, platform transparency, ease of access, customer feedback, and overall patient experience
